HSTO News and Press, Histogen Inc. From 10/27/20

Histogen Receive s IND A pproval from FDA to Initiate a Phase 1 Study of Emricasan in M ild-COVID - 19 Patients to Assess Safety and Tolerability Amerimmune to Lead Development Efforts of Emricasan in a ...

SAN DIEGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today an...

Dosing has been completed in a Phase 1b/2a clinical trial evaluating Histogen's (HSTO) lead candidate HST-001 for the treatment of androgenic alopecia (male pattern baldness).36 subjects, randomized 2:1 to receive HST-001 or placebo, received a total of 20 injections, 10 in the vertex scalp r...

SAN DIEGO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today an...

Histogen's ([[HSTO]] +0.7%) HST-002 is now designated as drug-biologic-device combination product by Office of Combination Products, a division of the FDA. In April of 2020, Histogen had submitted an Investigational Device Exemption application for HST-002 based upon its primary mec...

HST-002 Designated as Drug-Biologic-Device Combination Product HST -001 1b/2a Trial f or Androgenic Alopecia i n Men o n Track f or Top Line Data Results i n ...

Gainers:  Arrowhead Pharmaceuticals (NASDAQ: ARWR ) +47% . More news on: Arrowhead Pharmaceuticals, Inc., Eastman Kodak Company, Myomo, Inc., Stocks on the move, , Read more ...

Histogen (NASDAQ: HSTO ) has been awarded a $2M grant by the U.S. Department of Defense (DoD) to help fund a Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee. More news on: Histogen Inc., Healthcare stocks news, Stocks on the move, Read more ...

Investigational New Drug (IND) Filing Expected in the Fourth Quarter of 2020 SAN DIEGO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body...

Histogen ( HSTO ) has  completed patient dosing for the week 6 treatment timepoint in its Phase 1b/2a trial of HST-001 for the treatment of androgenic alopecia (pattern baldness) in men. More news on: Histogen Inc., Healthcare stocks news, Read more ...